HCPCS code J2860: Injection, siltuximab, 10 mg billing guide

Key Takeaways

HCPCS code J2860 describes Injection, siltuximab, 10 mg (brand name Sylvant), billed per 10 mg unit administered

Each billing unit equals 10 mg; dose is weight-based at 11 mg/kg every 3 weeks, so unit counts vary significantly by patient weight

Medicare Part B reimburses J2860 at ASP+6%; prior authorization is required by most commercial payers and has been updated by UHC for 2026

Pabau’s claims management software streamlines J-code claim submission, tracks units, and reduces denials for practices billing injectable biologics

HCPCS code J2860 has a single official long description: Injection, siltuximab, 10 mg. It is a Level II HCPCS J-code, assigned to drugs administered by a route other than oral. The code covers siltuximab sold under the brand name Sylvant, a chimeric monoclonal antibody that inhibits interleukin-6 (IL-6).

The CMS HCPCS Level II coding system maintains J2860 as the definitive billing code for this drug across all Medicare payer types and most commercial plans.

Siltuximab (Sylvant): Drug overview and FDA-approved indications

Siltuximab is a chimeric (human-murine) monoclonal antibody that binds and neutralizes IL-6, a pro-inflammatory cytokine central to the pathogenesis of Multicentric Castleman Disease. The FDA approved Sylvant specifically for MCD in patients who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Billing outside this indication carries significant coverage risk.

For billing staff, the clinical context shapes every claim. MCD is a rare lymph node disorder driving overproduction of IL-6. Confirmed diagnosis, HIV-negative and HHV-8-negative status, and documented disease progression are the clinical facts that support medical necessity on a J2860 claim. The NCI SEER CanMED HCPCS database cross-references J2860 with NDC codes and dosing data for oncology billing reference.

• Mechanism: Binds soluble and membrane-bound IL-6, preventing cytokine signaling that drives MCD symptoms
• Route of administration: Intravenous infusion over 1 hour
• Standard dose: 11 mg/kg every 3 weeks; dose adjusted by actual body weight
• Vial sizes: 100 mg and 400 mg single-dose vials (verify current NDC availability)
• Off-label use: Not covered by Medicare or most commercial plans; billing J2860 for non-MCD indications requires robust documentation and appeals readiness

How to calculate billing units for J2860

Units for HCPCS code J2860 are calculated per 10 mg of siltuximab actually administered. The dose is weight-based at 11 mg/kg, which means every patient weight produces a different unit count. This is where most billing errors occur: coders round incorrectly, fail to account for partial vial waste policies, or base units on the prescribed dose rather than the administered dose.

The calculation formula: Dose (mg) = Patient weight (kg) x 11 mg/kg. Units billed = Dose administered (mg) divided by 10, rounded to the nearest whole unit per your payer’s waste policy.

Rounding rules differ by payer. Medicare generally allows billing for the full vial when the remaining drug cannot be reused (single-dose vials), under the CMS drug wastage policy. Document the administered dose, the vials opened, and the amount discarded in the infusion record. Payer-specific waste policies for commercial plans vary considerably; verify before submitting.

NDC codes for siltuximab (Sylvant)

Most payers require the National Drug Code (NDC) on the claim line for physician-administered drugs billed under J-codes. Submitting J2860 without a valid NDC is one of the most common reasons for technical claim rejection. The NDC must reflect the actual vial dispensed and administered.

Sylvant is available in two vial sizes. NDC numbers are subject to change when manufacturers update labeling or packaging. Verify current NDCs against the FDA drug label or the NCI SEER CanMED HCPCS database before each billing cycle, and do not treat the table below as exhaustive or permanently current.

On the CMS-1500 claim form, report the NDC in field 24A using the qualifier N4 in the shaded area, followed by the 11-digit NDC, the quantity dispensed, and the unit of measure qualifier. Claims submitted without the NDC qualifier format often fail front-end edits before reaching the adjudicator.

Medicare reimbursement and ASP pricing for J2860

Medicare Part B pays for physician-administered drugs like siltuximab using the Average Sales Price (ASP) methodology. The payment rate for J2860 is ASP+6% per unit (per 10 mg). Because ASP is updated quarterly, the dollar amount per unit changes four times per year. Always pull the current quarter’s ASP pricing from the CMS Physician Fee Schedule lookup before setting patient estimates or calculating expected reimbursement. Practices using claims management software can flag J-code line items for quarterly price verification automatically.

Place of service affects the reimbursement rate. A J2860 claim billed from a physician office (POS 11) reimburses differently than the same drug administered in a hospital outpatient department (POS 22).

Physician offices generally receive the standard ASP+6% rate. Hospital outpatient departments are paid under the Outpatient Prospective Payment System (OPPS), which assigns siltuximab to an Ambulatory Payment Classification (APC) rather than the ASP formula. Practices need to confirm their enrollment status and the POS code they are authorized to bill before submitting.

Reviewing your electronic remittance advice after each J2860 claim adjudicates is the fastest way to catch systematic reimbursement discrepancies before they compound across a quarter’s worth of infusion visits.

Buy-and-bill model for J2860 siltuximab

Siltuximab is typically administered under the buy-and-bill model: the practice acquires Sylvant directly, administers it to the patient, and bills the payer for both the drug (J2860) and the infusion administration service (CPT codes 96413 and 96415).

Understanding the full revenue cycle management chain for buy-and-bill reduces cash flow risk on a drug that costs thousands of dollars per infusion cycle.

1. Drug acquisition: Order Sylvant through a specialty pharmacy or specialty distributor. Verify current contract pricing; AWP is a reference benchmark, not the actual acquisition cost, and the two figures can differ substantially.
2. Storage and handling: Store per FDA labeling requirements. Document storage temperatures and lot numbers for each vial; this documentation supports audit defense and wastage billing.
3. Patient weight check: Record actual body weight at each visit. Siltuximab dosing is recalculated at every cycle based on current weight, so a weight change directly affects the unit count billed.
4. Administration: Administer as a 1-hour IV infusion. Document start time, stop time, administered dose (mg), and any adverse events in the encounter record. Pair J2860 with CPT 96413 for the initial hour and CPT 96415 for each additional hour if the infusion runs long.
5. Claim submission: Submit J2860 with the calculated unit count, the NDC qualifier in field 24A, the supporting ICD-10 diagnosis code, and any required prior authorization number. Pair with the administration CPT code on the same claim. Use the correct POS code for your setting.

Good superbill documentation for each infusion visit captures the dose ordered, the dose administered, the vials used, and any waste amount. This single document supports both the J-code unit count and any wastage billing on the same claim.

Streamline injectable biologic billing with Pabau

Pabau’s claims management software tracks J-code units, flags NDC requirements, and automates remittance reconciliation so your billing team spends less time chasing denials on high-cost drugs like siltuximab.

Book a demo

Prior authorization requirements for J2860

Prior authorization (PA) is required for siltuximab by most commercial payers and is increasingly common for Medicare Advantage plans. The PA burden for J2860 reflects both the drug’s cost and the rarity of its approved indication. Eligibility verification before each infusion cycle is essential; patients can switch plans mid-treatment, and a lapsed PA number is a leading cause of J2860 denials.

When a PA is denied, the appeal should include the pathology report confirming MCD, serology results ruling out HIV and HHV-8, and the prescribing oncologist’s clinical rationale. PA requirements and their documentation lists change regularly; always verify directly with the payer rather than relying on historical approvals.

Staying current with medical billing compliance updates from your MAC and commercial payers is the most reliable way to avoid PA-related claim holds.

ICD-10 diagnosis codes that support J2860 medical necessity

Pairing J2860 with the correct ICD-10 diagnosis code is not optional. Without a supported diagnosis on the claim, the drug line will deny for lack of medical necessity regardless of whether a PA was obtained. Castleman disease maps to a specific code in ICD-10-CM, and coders should verify it against the current fiscal year’s tabular list rather than relying on memory.

D47.Z2 is the most widely accepted code for MCD, but MAC-specific LCDs may specify additional documentation requirements tied to this diagnosis. Some plans require the pathology report to use the specific histologic subtype language (hyaline vascular, plasma cell, or mixed variant) in addition to the ICD-10 code. Review the current LCD for your MAC jurisdiction before submitting the first claim for a new patient.

Related HCPCS and CPT codes for siltuximab infusions

J2860 covers only the siltuximab drug cost. The infusion administration service requires a separate CPT code on the same claim. Submitting the drug code without the administration code, or using the wrong administration code, results in a payment reduction or denial for the administration component.

The AAPC Codify HCPCS lookup provides coding guidance and related code crosswalks for J2860 that billing staff can reference when confirming the correct administration code pairing for their payer contracts.

Claim submission tips and common billing errors for HCPCS code J2860

Most J2860 claim errors are preventable. The drug’s complexity (weight-based dosing, NDC reporting, PA requirements, and dual-code submission) creates multiple checkpoints where a single missed element causes a denial or delay. The denial codes in medical billing most frequently associated with J-code claims fall into three buckets: technical rejections from missing data elements, medical necessity denials from diagnosis mismatches, and unit errors from incorrect dose calculations.

• Missing NDC qualifier: Always include the N4 qualifier, the 11-digit NDC, the quantity administered, and the unit of measure in field 24A shaded area. A missing qualifier triggers an automatic front-end rejection before the claim is even adjudicated.
• Wrong unit count: Recalculate from current body weight at every cycle. If the patient gained or lost weight since the last infusion, the unit count changes. Submitting last cycle’s units on this cycle’s claim is both a billing error and a documentation compliance risk.
• No PA number on the claim: When PA is required, the authorization number must appear in box 23 of the CMS-1500 or the equivalent EDI field. Omitting it produces an instant denial even when the PA itself was approved.
• POS mismatch: Billing POS 11 for an infusion performed in a hospital outpatient department incorrectly inflates reimbursement and triggers post-payment audit flags. Use the POS that reflects where the service actually occurred.
• Administration code missing: J2860 without an accompanying CPT 96413 on the same claim will leave the administration service unpaid entirely. Some practices submit them on separate claim forms by error; they must be on the same claim.
• Expired PA on repeat cycles: Siltuximab is given every 3 weeks indefinitely while the patient responds. PA authorizations often cover a defined number of cycles or a fixed time period. Track PA expiration dates and initiate renewal at least 2 weeks before the authorization lapses.

Robust denial management processes that track J-code denial patterns by denial reason code let billing teams identify whether the practice has a systemic issue (such as consistent NDC omissions or unit miscalculations) versus random individual errors.

Pulling a monthly report of J2860 denials sorted by CARC/RARC reason code takes minutes in most billing systems and exposes patterns that would otherwise stay hidden in the claim queue. Ensuring every submission meets the standards for submitting a clean claim on the first pass is the single most effective way to reduce J2860 payment delays.

Practices that also ensure HIPAA compliance for medical offices throughout the infusion documentation process protect themselves against both payer audits and patient data exposure risks that can arise when handling high-cost biologic claims with detailed clinical records.

Conclusion

HCPCS code J2860 is a precision billing code: every element on the claim, from the unit count to the NDC to the PA number, must be correct or payment delays follow. The weight-based dosing, quarterly ASP updates, and payer-specific PA requirements make siltuximab one of the more administratively demanding drugs in an outpatient oncology or hematology practice.

Pabau’s claims management software helps practices billing injectable biologics track J-code units, validate NDC fields, and monitor remittance data so the billing team catches errors before they age into write-offs. To see how it fits your infusion billing workflow, book a demo.

Continue your research

Need a framework for cleaner biologic claims? Medical billing workflow guide covers the end-to-end claim lifecycle from charge capture through remittance reconciliation.

Getting hit with unexplained remittance adjustments? Understanding electronic remittance advice explains how to read ERA files and match adjustment reason codes to the correct action.

Want to reduce J-code denial rates systematically? Denial management in healthcare outlines a structured approach to tracking, appealing, and preventing recurring claim denials.

Frequently Asked Questions